© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
An expert cardiologist, sleep specialist, and pulmonologist, share insights on the awareness and treatment of sleep disorders, including insomnia, that co-occur with other health conditions.
October 12th 2022
Dr Nathaniel F. Watson, MD, provides insight on the prevalence of various sleep disorders, including insomnia, and patient populations at high-risk for developing these disorders.
Ashgan A. Elshinawy, DO, leads a discussion on the co-occurrence and relationship between sleep disorders and different health conditions in patients.
October 14th 2022
Nathaniel F. Watson, MD; Ashgan A. Elshinawy, DO; and C. Michael Gibson, MD, examine complications patients encounter with sleep disorders, including for insomnia, and the impact on their quality of life.
Dr Nathaniel F. Watson reviews screening patients for sleep disorders and referral to sleep specialists.
October 17th 2022
Experts in sleep medicine stress the importance of early diagnosis of sleep disorders and how they approach treatment in their clinics.
Ashgan A. Elshinawy, DO, comments on engaging patients in conversations around managing sleep disorders with co-occurring health conditions.
October 19th 2022
Dr Ashgan A. Elshinawy and C. Michael Gibson considers safety and efficacy factors when approaching treatment selection for sleep disorders and insomnia.
Nathaniel F. Watson, MD, reviews the pathways involved in sleep and wakefulness cycles as it relates to sleep disorders.
October 21st 2022
Drs Ashgan A. Elshinawy, C. Michael Gibson, and Nathaniel F. Watson discuss FDA-approved medications currently used for the treatment of sleep disorders and insomnia, and comment on the difference between DORAs.
Nathaniel F. Watson, MD, highlights the use of daridorexant for treating patients with insomnia as seen from phase 3 trials and data presented at the World Sleep 2022 meeting and managing adverse events.
Paul Feuerstadt, MD: The Future of RBX2660
Fighting for Sight: Geographic Atrophy Drug Development Meets Its Future
Aflibercept Outperforms Bevacizumab at Weaning nAMD Patients Off Treatment